1283P Predicting the differential diagnosis of pneumonitis in stage IV non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs) by combining clinical and radiomic features

ICI-induced pneumonitis is a severe side effect occurring in 4-10% of the patients, requiring an appropriate diagnosis for management with steroids. The differential diagnosis between ICI-related (ICI-R) and other causes of pneumonitis (OP) remains challenging. We therefore developed a prediction model including clinical and radiomic parameters for the differential diagnosis of pneumonitis in stage IV NSCLC patients.